Our computational framework results 66 are consistent with recent clinical evidence from the phase 3 EVOKE and EVOKE+ trials (NCT04777396, NCT04777409), which are the first large-scale, randomized, double-blind, placebo-controlled studies designed to evaluate the disease-modifying potential of semaglutide in early-stage symptomatic AD 67,68
Importantly, impaired adipogenesis and limited adipose tissue expandability have emerged as critical determinants of lipid spillover, potentially representing early indicators of metabolic disease risk [21]
What This Means for You How the Weight-Loss Pathway Opened Up From Announcement to Live Program On November 6, 2025 , the Trump administration announced agreements with Eli Lilly and Novo Nordisk to expand Medicare coverage of GLP-1 medications (a class of weight loss and diabetes drugs including Wegovy, Ozempic, and Zepbound) for obesity
Why Results Vary With GLP-1
These estimates typically apply to off-label use for weight loss and may not be covered by standard health insurance policies
But it is also approved by the Food and Drug Administration (FDA) to lower the risk of cardiovascular events in adults with heart disease who have excess weight or obesity, and to treat adults with an advanced liver disease known as metabolic-associated steatohepatitis (MASH)
